Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

Management of Penetrating Aortic Ulcer (PAU) with Associated Intramural Hematoma (IMH)

Diagnosis and Risk Stratification

  • The European Society of Cardiology recommends that PAU in the ascending aorta with associated IMH has a 33-75% rupture risk, necessitating urgent surgical repair 1, 2
  • The presence of IMH with PAU represents a high-risk feature that may be a precursor to aneurysm rupture, according to the European Heart Journal 3, 1, 2
  • PAU associated with IMH is explicitly listed as a high-risk feature warranting consideration for intervention even in the absence of other complications, as stated by the European Society of Cardiology 3, 4

Initial Medical Management

  • The European Society of Cardiology recommends immediate aggressive medical therapy for all patients with PAU-IMH, with hemodynamic targets including heart rate ≤60 beats per minute and systolic blood pressure <120 mmHg 3, 1, 2, 4
  • The American College of Cardiology suggests using intravenous beta-blockers as first-line therapy to achieve a heart rate ≤60 beats per minute 4
  • The European Society of Cardiology advises against initiating vasodilators before achieving heart rate control, as reflex tachycardia will increase aortic wall stress 4

Diagnostic Approach

  • Contrast-enhanced CT is the diagnostic technique of choice with 96% sensitivity for detecting IMH associated with PAU, according to the Journal of the American College of Radiology and the European Society of Cardiology 6, 4, 5
  • The classic PAU appearance is a mushroom-shaped protrusion with overhanging edges penetrating through the internal elastic lamina, as described by the European Society of Cardiology 4

Indications for TEVAR in Type B PAU-IMH

  • The European Society of Cardiology recommends TEVAR for complicated Type B PAU-IMH, defined by recurrent or persistent pain despite medical therapy, expansion of the IMH on serial imaging, periaortic hematoma, intimal disruption, or presence of high-risk imaging features 3, 1, 2
  • For uncomplicated Type B PAU-IMH, TEVAR should be considered (Class IIa recommendation) given the inherently high-risk nature of this combination, as stated by the European Society of Cardiology 3, 1

Surveillance Strategy

  • The European Society of Cardiology recommends repeat imaging (CT or MRI) at 1 month after diagnosis, then at 3, 6, and 12 months, and annually thereafter if stable, for patients managed medically (uncomplicated Type B PAU-IMH without intervention) 3, 4, 5

Long-Term Medical Management

  • The European Society of Cardiology advises indefinite medical therapy for all PAU-IMH patients, including strict blood pressure control (systolic <120 mmHg) indefinitely, LDL-C reduction by ≥50% with goal <55 mg/dL using moderate-to-high intensity statins, and low-dose aspirin 75-162 mg daily to reduce cardiovascular events 4